Source: Health Products Regulatory Authority (IE) Revision Year: 2020 Publisher: Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes Cedex, France
Diamicron MR 30 mg modified-release tablets.
| Pharmaceutical Form |
|---|
|
Modified release tablet. White, oblong tablet engraved on both faces, ‘DIA 30’ on one face and Servier logo on the other. |
One tablet contains gliclazide 30 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Gliclazide |
Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. |
| List of Excipients |
|---|
|
Calcium hydrogen phosphate dihydrate, |
7, 10, 14, 20, 28, 30, 56, 60, 84, 90, 100, 112, 120, 180 and 500 tablets in Aluminium/Poly(vinylchloride) blister, packed in cardboard boxes.
Not all pack sizes may be marketed.
Les Laboratoires Servier, 50, rue Carnot, 92284 Suresnes Cedex, France
PA0568/013/001
Date of first authorisation: 24 November 2000
Date of last renewal: 29 March 2010
| Drug | Countries | |
|---|---|---|
| DIAMICRON | Austria, Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Spain, France, Hong Kong, Ireland, Italy, Malta, Mexico, Nigeria, Netherlands, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
